Biotech Insider Buying: Merrimack Pharmaceuticals (NASDAQ:MACK), Omeros (NASDAQ:OMER), Insys Therapeutics (NASDAQ:INSY), Agios Pharmaceuticals (NASDAQ:AGIO), BioTime (NYSEMKT:BTX)

Merrimack Pharmaceuticals Inc (NASDAQ:MACK) Director Gary L. Crocker bought 36,000 shares of the stock in a transaction dated Monday, June 23rd. The shares were purchased at an average price of $6.84 per share, with a total value of $246,240.00. Merrimack Pharmaceuticals Inc (NASDAQ:MACK) stock performance was 3.91% in last session and finished the day at $7.44. Traded volume was 1.38million shares in the last session … Continue reading Biotech Insider Buying: Merrimack Pharmaceuticals (NASDAQ:MACK), Omeros (NASDAQ:OMER), Insys Therapeutics (NASDAQ:INSY), Agios Pharmaceuticals (NASDAQ:AGIO), BioTime (NYSEMKT:BTX)

Small Cap Insider Buying: Hercules Offshore (NASDAQ:HERO), Merrimack Pharmaceuticals (NASDAQ:MACK), Omeros Corporation (NASDAQ:OMER), Insys (NASDAQ:INSY), New Mountain Finance (NYSE:NMFC)

Hercules Offshore Inc (NASDAQ:HERO) Director Thomas R. Bates, Jr. purchased 20,000 shares of the stock on the open market in a transaction that occurred on Tuesday, June 24th. The stock was purchased at an average price of $3.93 per share, for a total transaction of $78,600.00. Following the completion of the transaction, the director now directly owns 280,000 shares in the company, valued at approximately … Continue reading Small Cap Insider Buying: Hercules Offshore (NASDAQ:HERO), Merrimack Pharmaceuticals (NASDAQ:MACK), Omeros Corporation (NASDAQ:OMER), Insys (NASDAQ:INSY), New Mountain Finance (NYSE:NMFC)

Biotech Insider Buying: OvaScience Inc (NASDAQ:OVAS), BioTime (NYSEMKT:BTX), Insys Therapeutics (NASDAQ:INSY), Novavax (NASDAQ:NVAX), ImmuCell Corporation (NASDAQ:ICCC)

Ovascience Inc (NASDAQ:OVAS) major shareholder Fund L.P. Longwood bought 100,000 shares of the company‚Äôs stock on the open market in a transaction dated Friday, March 7th. The stock was purchased at an average cost of $10.00 per share, for a total transaction of $1,000,000.00. OvaScience Inc (NASDAQ:OVAS) stock performance was -2.98% in last session and finished the day at $8.47. Traded volume was 69,618.00million shares … Continue reading Biotech Insider Buying: OvaScience Inc (NASDAQ:OVAS), BioTime (NYSEMKT:BTX), Insys Therapeutics (NASDAQ:INSY), Novavax (NASDAQ:NVAX), ImmuCell Corporation (NASDAQ:ICCC)

NASDAQ Insider Buying: Prospect Capital (NASDAQ:PSEC), CyrusOne (NASDAQ:CONE), National Penn Bancshares (NASDAQ:NPBC), Insys Therapeutics (NASDAQ:INSY), Bank Of The Ozarks (NASDAQ:OZRK)

Prospect Capital Corp. (NASDAQ:PSEC) CEO John F. Barry purchased 100,000 shares of the stock in a transaction dated Friday, June 13th. The stock was purchased at an average cost of $10.37 per share, for a total transaction of $1,037,000.00. Following the completion of the purchase, the chief executive officeronline.wsj.comchief executive officer now directly owns 4,110,959 shares in the company, valued at approximately $42,630,645. Prospect Capital … Continue reading NASDAQ Insider Buying: Prospect Capital (NASDAQ:PSEC), CyrusOne (NASDAQ:CONE), National Penn Bancshares (NASDAQ:NPBC), Insys Therapeutics (NASDAQ:INSY), Bank Of The Ozarks (NASDAQ:OZRK)

Biotech Losers: Insys Therapeutics Inc (NASDAQ:INSY), Enzymotec Ltd (NASDAQ:ENZY), Geron Corporation (NASDAQ:GERN), Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)

Insys Therapeutics, Inc. (NASDAQ:INSY)’s shares have been under pressure recently on news regarding prescribing patterns for Subsys. The stock price of the company tumbled 17.41% and 15.45% in the last two consecutive trading sessions. Insys Therapeutics Inc (NASDAQ:INSY) stock performance was -15.70% in last session and finished the day at $23.01. Traded volume was 3.24million shares in the last session and the average volume of … Continue reading Biotech Losers: Insys Therapeutics Inc (NASDAQ:INSY), Enzymotec Ltd (NASDAQ:ENZY), Geron Corporation (NASDAQ:GERN), Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)

Biotech Volatile Stocks: Lexicon Pharmaceuticals (NASDAQ:LXRX), Corcept Therapeutics Incorporated (NASDAQ:CORT), Insys Therapeutics (NASDAQ:INSY), ANI Pharmaceuticals (NASDAQ:ANIP)

Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX), just announced a positive, top-line result in a Phase 2 clinical trial of their experimental therapy LX4211 in type 1 diabetes. LX4211, an oral, first-in-class, dual inhibitor of sodium glucose transporters 1 and 2, was designed to lower blood glucose levels through two insulin-independent mechanisms of action. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) stock performance was 5.16% in last session and finished the … Continue reading Biotech Volatile Stocks: Lexicon Pharmaceuticals (NASDAQ:LXRX), Corcept Therapeutics Incorporated (NASDAQ:CORT), Insys Therapeutics (NASDAQ:INSY), ANI Pharmaceuticals (NASDAQ:ANIP)